The 340B program is at a crossroads. With ongoing litigation, administrative shifts, and regulatory uncertainty, drug manufacturers face a complex and uncertain environment. At the same time, issues like program diversion and duplicate discounts continue to escalate, highlighting the need for better data quality and higher transparency.
How can manufacturers regain control of these challenges as new models remain in limbo? What actionable steps can be taken under current guidelines to drive meaningful change? And why are contract pharmacy restrictions insufficient to address the core issues?
You'll learn:
- Gain insights from industry experts on the impact of current litigation and regulatory uncertainty
- Understand why existing measures, like contract pharmacy restrictions, fall short of resolving critical challenges
- Discover practical strategies to manage 340B program exposure in this evolving landscape
- Experience a live demo of Truzo’s 340B Discount Monitoring solution and see how it empowers manufacturers to navigate these complexities with confidence
